Page 5,025«..1020..5,0245,0255,0265,027..5,0305,040..»

Breakthrough Stem Cell Therapy to Be Presented at the Global Life Sciences Conference in Warsaw

Posted: Published on July 26th, 2013

WROCLAW, POLAND--(Marketwired - Jul 25, 2013) - Stem Cells Spin S.A., Central and Eastern Europe's leading stem cell biotechnology company with significant funding from the European Union will present at the upcoming 1st Global Life Sciences Conference in Warsaw, Poland on September 16-17th at the Warsaw Stock Exchange. Janislaw Muszynski, President of Stem Cells Spin S.A., dr. hab. Marek Cegielski, Vice President, Research and Development Director and Lawrence Wolf, partner of Wolf & Wolf Inc., Boca Raton, FL; U.S. marketing advisor will discuss current research and future plans for a major expansion into North American markets. Founded by scientists from Wroclaw Medical University, Stem Cells Spin S.A. is focused on the development and production of natural regenerative products derived from mammalian stem cells. The company currently markets a line of biodermocosmetics under the brand name of Revitacell andveterinary products under the brand name of Velvetyna. Additionally, the company is pursuing major research on human medical applications. Warsaw, the financial capital of Central and Eastern Europe is a major center of life science investment. Over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe will attend the conference to discuss and assess new investment opportunities. … Continue reading

Comments Off on Breakthrough Stem Cell Therapy to Be Presented at the Global Life Sciences Conference in Warsaw

Andrea Chen, MD, Joins The Rendon Center for Dermatology and Aesthetic Medicine in Boca Raton

Posted: Published on July 26th, 2013

BOCA RATON, Fla., July 25, 2013 /PRNewswire/ --The Rendon Center for Dermatology and Aesthetic Medicine has announced the addition of Andrea Chen, MD, to the staff starting July 1, 2013. Dr. Chen specializes in Mohs micrographic surgery for skin-cancer, and in cosmetic surgical and laser procedures. Dr. Chen graduated Phi Beta Kappa from the University of Chicago with a degree in Biological Sciences. She obtained her MD from New York University, where she was inducted into the Alpha Omega Alpha honor society.During this period, she conducted research in melanoma at the University of Louisville and co-authored several papers. Following an internship in internal medicine at the University of Louisville (KY), Dr. Chen completed her residency in dermatology at the University of Miami (FL), where she received an award for excellence in resident teaching, and participated in research on the healing of chronic leg wounds. Dr. Chen then completed a fellowship in Mohs micrographic surgery. Dr. Chen is board-certified in dermatology, a Fellow of the American Academy of Dermatology and a Fellow-elect of the American College of Mohs Surgery. * * * * * About the Rendon Center for Dermatology and Aesthetic MedicineThe Rendon Center for Dermatology & Aesthetic Medicine inBoca … Continue reading

Posted in Aesthetic Medicine | Comments Off on Andrea Chen, MD, Joins The Rendon Center for Dermatology and Aesthetic Medicine in Boca Raton

Stem Cell Treatments for Autism – 3-year update from Millie Jimenez – Video

Posted: Published on July 26th, 2013

Stem Cell Treatments for Autism - 3-year update from Millie Jimenez Millie Jimenez gives an update on her twin boys' (Angelo and Anthony) improvements since their first umbilical cord stem cell treatments at the Stem Cell Ins... By: http://www.cellmedicine.comContinue reading

Posted in Stem Cell Treatments | Comments Off on Stem Cell Treatments for Autism – 3-year update from Millie Jimenez – Video

Christiano fights for life after operation

Posted: Published on July 26th, 2013

WA Derby winner Alta Christiano is fighting for his life after suffering an adverse reaction to stem-cell treatment. The Gary Hall Sr-trained star has been closely monitored at the Lark Hill Veterinary Clinic since the procedure two weeks ago. Connections opted for the treatment to repair Alta Christiano's near fore suspensory ligament, which he tore after a Byford trial win in May. The three-year-old is unbeaten from three starts in WA after a syndicate of Hall's clients bought an 80 per cent share in him from New Zealand owners. He scored a brilliant win over Macha in the $200,000 WA Derby (2536m) at Gloucester Park in April. "We don't know if he'll pull through, but we're hoping," Hall said. "He's still under constant treatment. We're not sure if he picked up an infection or had a bad reaction to the stem-cell treatment." Hall is hoping for a change of fortune at Gloucester Park tonight. He has Real Hammer and Heez Orl Black taking on smart three-year-old Condrieu in the feature race, the $35,000 John Higgins Memorial (2130m). The Greg and Skye Bond-trained Condrieu, a winner of three of his past five starts, is the one to beat from barrier three. … Continue reading

Comments Off on Christiano fights for life after operation

Stem cell transplant gives hope to leukemia patient

Posted: Published on July 26th, 2013

HALIFAX Janice Davidson is getting a new lease on life. On Thursday night, the 39-year-old leukemia patient will undergo a stem cell transplant from an anonymous donor in Halifax. You cant believe there is someone out there in the world who you dont know who is willing to give you a gift that is like no other really, the mother of three said. Davidson was diagnosed with leukemia five years ago. Since then, she has tried several different treatment options and relapsed twice. A stem cell transplant is now her best option to beat the disease. Its not going to be an easy path but we know were on the right path, she said. We know what we need to do and we are very hopeful for the future. The latest figures from One Match, the national program for blood stem cell donors and recipients, show that there are about 750 Canadians waiting to receive a stem cell transplant. Eight of those are in Nova Scotia. Factors such as genetics, ethnic background and treatment affect wait time in receiving a transplant so Davidson is extremely thankful that she found a match. It is especially fortunate because her three siblings were … Continue reading

Comments Off on Stem cell transplant gives hope to leukemia patient

Loyola's Alcohol Research Program receives 4 NIH grants totaling more than $3 million

Posted: Published on July 26th, 2013

Public release date: 24-Jul-2013 [ | E-mail | Share ] Contact: Jim Ritter jritter@lumc.edu 708-216-2445 Loyola University Health System MAYWOOD, Il. The Alcohol Research Program at Loyola University Chicago Stritch School of Medicine recently received four research grants, totaling more than $3 million, from the National Institutes of Health. A fifth grant is pending notification of the award. Following, for each of the four grants, are the name of the principal investigator, name of the grant, number of years, total dollar amount and type of grant. Mashkoor Choudhry, PhD, "Alcohol Intoxication and Postburn Intestinal Immunity," $2,309,873, five years, R01. John Callaci, PhD, "Alcohol Effects on SDF1-Mediated Stem Cell Homing Following Bone Fracture," $396,376, two years, R21. Gwendolyn Kartje, MD, PhD, "The Effects of Binge Ethanol on Neuroinflammation/Functional Recovery after Traumatic Brain Injury," $330,750, two years, R21. Jill Ippolito, "Ethanol, Lung Mesenchymal Stem Cells and Pulmonary Inflammation After Burn Injury" $97,125, three years, F31 Loyola's nationally recognized Alcohol Research Program investigates such issues as how heavy drinking hinders the body's ability to recover from burns or trauma; how alcohol abuse damages bones and whether teen binge drinking can increase the risk of mood disorders later in life. Read more: Loyola's Alcohol … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Loyola's Alcohol Research Program receives 4 NIH grants totaling more than $3 million

Sarepta falls on plans for early 2014 drug filing

Posted: Published on July 25th, 2013

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review LiveRoom Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials The Lookout Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Lookout The Sideshow Around the World Katie's Take Power Players This Could Be Big Newsmakers Trending Now Just … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta falls on plans for early 2014 drug filing

Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of …

Posted: Published on July 25th, 2013

CAMBRIDGE, MA--(Marketwired - Jul 24, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).Eteplirsen is Sarepta's lead exon-skipping compound in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51. The decision to submit an NDA for eteplirsen in 2014 is based on productive interactions with the FDA in a meeting that occurred this week.That meeting was a follow-up to the FDA's review of two recently submitted summary documents that included data on dystrophin and clinical outcomes from the existing eteplirsen studies.The FDA stated in pre-meeting comments that the Agency is "open to considering an NDA based on these data for filing."The Agency, however, requested additional information related to the methodology and verification of dystrophin quantification.Sarepta believes the requests from the Agency can be addressed and incorporated into an NDA submission in the first half of 2014. "We are encouraged by the feedback from the FDA and believe that data … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of …

Sarepta Falls on Investor Skepticism of Approval Plans

Posted: Published on July 25th, 2013

Sarepta Therapeutics (SRPT) Inc. plummeted the most in 14 months on investor concerns that U.S. regulators wont consider the companys treatment for Duchenne muscular dystrophy on an accelerated basis. Sarepta, with no products on the market, fell 12 percent to $40.95 at 11:11 a.m. The shares of the Cambridge, Massachusetts-based company declined as much as 17 percent, their biggest intraday drop since May 2012, after at least three analysts cut their ratings on the stock. The biotechnology company announced today it plans to seek approval of eteplirsen in the first half of 2013 after the Food and Drug Administration said it was open to a filing based on data from existing studies. The agency requested information on methodology and verification that will be incorporated into the filing, the company said in a statement today. Regulators didnt commit to considering approval of the compound on an accelerated approval basis, Sarepta said. If youre a bear, you believe that the FDA is just saying file, and the management is filing just because they can, not because they think theyre going to get approved, Robyn Karnauskas, a New York-based analyst at Deutsche Bank AG, said in a telephone interview. She reduced her rating … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Falls on Investor Skepticism of Approval Plans

TribTalk: Is Utah’s free autism program working? – Video

Posted: Published on July 25th, 2013

TribTalk: Is Utah's free autism program working? Late last year, the Utah Department of Health launched a pilot program that provides free autism treatment for 250 children with autism, selected by lottery.... By: sltrib … Continue reading

Comments Off on TribTalk: Is Utah’s free autism program working? – Video

Page 5,025«..1020..5,0245,0255,0265,027..5,0305,040..»